RT Journal Article
SR Electronic
T1 Short Report: Investigating Oropouche as a possible etiology for fevers of unknown origin in a clinical cohort from Colombia, 2013-2015
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.06.24316756
DO 10.1101/2024.11.06.24316756
A1 Walsh, Christine S.
A1 Cardenas, Jenny C.
A1 Gutierréz-Silva, Lady Y.
A1 González, Maria U.
A1 Mores, Christopher N.
A1 Londono-Renteria, Berlin
A1 Christofferson, Rebecca C.
YR 2024
UL http://medrxiv.org/content/early/2024/11/08/2024.11.06.24316756.abstract
AB Currently, the largest outbreak of Oropouche virus (OROV) in Latin America and the Caribbean, has also spread across the globe to Italy, Spain, and Germany, bringing this virus into the public domain. With over 8,000 cases and counting in Brazil, there have been two deaths in young women with no known comorbidities, and infection with Oropouche was associated with a late term stillbirth. While OROV has been sporadically detected in Colombia since 2017, with a handful of cases in Cúcuta and Leticia, the distribution of OROV prior to that remains unknown. Therefore, we undertook to test a clinical cohort of febrile patients from Colombia to determine if OROV was circulating within the human population earlier than previously determined. We screened 631 serum samples collected in 2014-2015 from three municipalities: Cúcuta, Los Patio, and Ocaña. We found evidence of OROV infection in three patients from Ocaña, though live virus was not recoverable from patient sera. These data suggest that OROV circulation, while sporadically detected in Colombia, has circulated earlier than previously thought. With the emergence and expansion of new or neglected viruses, there is a need to expand screening of febrile patients both retro- and prospectively to describe and better understand the distribution of arbovirus circulation in human populations. Surveillance for OROV across South America is necessary going forward, especially as the outbreak in Brazil continues.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Louisiana State University gave human subjects' approval for this work (LSU IRB protocol #3415)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript